Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: P.M.Freedman who wrote (1105)	8/17/1999 12:23:00 AM
From: William Partmann	Read Replies (1) \| Respond to of 1686

P.M. What law school did you go to? Have you read all the discovery in the case? Did you interview the attorneys for both side and their experts? Are you familiar with I.P. law especially as it relates to biotechnology. Or do you just read the rags? Get real. You have as much insight in this case as a squid does geometry.

To: P.M.Freedman who wrote (1105)	8/17/1999 6:52:00 AM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

PMF, Again, you have not indicated anything that points to Biogen being in a vulnerable position. Biogen has repeatedly won cases against Berlex, and for good reasons. While respecting your beliefs, I question their foundation: you have cited no facts. The company manufactures only Avonex for sale. However, the company does not consider itself a one-drug company - it does license and receive royalties on a $2B drug called IntronA and receives royalties on 2 other drugs as well. Personally, I appreciate your pointing out the stock's potential downside. But, I'm sure you can understand why some would get frustrated with your style: you don't cite facts, you often mention other stocks that you like much more, and you seem to make conclusions from statistics that do not necessarily follow.